NCT03111121View on ClinicalTrials.gov

Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy

PHASE4CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

May 4, 2017

Primary Completion Date

June 22, 2018

Study Completion Date

May 30, 2019

Conditions
MicrolaryngoscopyRigid Bronchoscopy
Interventions
DRUG

Sugammadex

receive reversal with sugammadex 4mg/kg

DRUG

neostigmine

receive reversal with neostigmine 0.04 mg/kg

DRUG

glycopyrrolate

receive reversal with glycopyrrolate (0.01 mg/kg)

Trial Locations (1)

26506

WVU Healthcare Ruby Memorial Hospital, Morgantown

All Listed Sponsors
lead

West Virginia University

OTHER

NCT03111121 - Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy | Biotech Hunter | Biotech Hunter